Drug Trial Radar · NCT07852962
Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants.
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Feb 10, 2027
Primary completion
Jul 18, 2027
Study completion Jul 18, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the drug levels, immune response, safety and tolerability of BMS-986446 in healthy Chinese participants.
Conditions
- Healthy Volunteers
Interventions
BMS-986446Drug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to Day 85
- Time of maximum observed plasma concentration (Tmax)Time frame: Up to Day 85
- Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]Time frame: Up to Day 85
- Geometric mean ratios of area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]Time frame: Up to Day 85
- Total body clearance in intravenous infusion (CLT)Time frame: Up to Day 85
- Volume of distribution of terminal phase in intravenous administration (Vz)Time frame: Up to Day 85
- Apparent terminal serum half-life [T-HALF]Time frame: Up to Day 85
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.